A Study of LY3493269 in Participants With Type 2 Diabetes

Part of paid clinical trials in Anaheim, California.

Sponsor
Eli Lilly and Company
Study ID
NCT04515576
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • LY3493269 — DRUG
    Administered SC
  • Dulaglutide — DRUG
    Administered SC
  • Placebo — DRUG
    Administered SC

Study Details

The main purpose of this study is to determine the side effects related to LY3493269 in participants with type 2 diabetes. Blood tests will be performed to check concentrations of LY3493269 in the bloodstream. Each enrolled participant will receive LY3493269, dulaglutide, or placebo. The study will last up to approximately 16 weeks for each participant and may include up to 11 visits.

Key Dates

Start date
Aug 25, 2020
Status verified
Dec 2024
Primary completion
Mar 9, 2021
Completion
Mar 9, 2021

Study Design

Enrollment
56 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Active Comparator: 1.5 milligrams (mg) Dulaglutide
    Participants received 1.5 mg dulaglutide subcutaneously (SC) once weekly (QW) for 4 weeks.
  • Experimental: 0.3 mg LY3493269
    Participants received 4 fixed dosed of 0.3 mg LY3493269 SC QW for 4 weeks.
  • Experimental: 1 mg LY3493269
    Participants received 4 fixed dosed of 1 mg LY3493269 SC QW for 4 weeks.
  • Experimental: 0.75/1.5/3 mg LY3493269
    Participants received LY3493269 0.75 mg on week 1, 1.5 mg on week 2 and 3 mg on week 3 and 4 SC as weekly doses.
  • Experimental: 1.5/3/4/5 mg LY3493269
    Participants received LY3493269 1.5 mg on week 1, 3 mg on week 2, 4 mg on week 3 and 5 mg on week 4 as weekly doses.
  • Placebo Comparator: Placebo
    Participants received placebo subcutaneously (SC) once weekly (QW) for 4 weeks.

Primary Outcome Measure

Number of Participants With One or More Treatment-Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Baseline through final follow-up at Day 57 ]

Locations (3)

FacilityCityStateZIPSite coordinators
Anaheim Clinical Trials, LLCAnaheimCalifornia92801-
Miami Research AssociatesMiamiFlorida33143-
Clinical Trials of Texas, Inc.San AntonioTexas78229-

Find similar trials in Anaheim, CA

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Anaheim Clinical Trials, LLC· Anaheim, CAMiami Research Associates· Miami, FLClinical Trials of Texas, Inc.· San Antonio, TX

Related Studies